As 2020 comes to a close, the NICA team has been busy fighting proposed and planned policy changes that threaten patient access and providers’ ability to serve them effectively. On the COVID-19 front, we have also been taking very big strides to assist in resource development for providers who plan to administer new COVID-19 antibody treatments.
Here’s a snapshot of what this past month looked like for us in terms of wins, new developments, and more.
United Healthcare Delayed Implementation of their Accumulator Adjustment – Medical Benefit Program
We’d like to kick off December’s Monthly Drip with a big advocacy win: In mid-November, UnitedHealthcare (UHC) officially delayed implementation of the Accumulator Adjustment – Medicare Benefit program for their commercial members. In addition to posts on our social media platforms and educational articles on our blog, NICA and IAF
signed on to a joint letter with Aimed Alliance
expressing concern over how the program would negatively impact patients’ ability to access medication and providers’ financial stability. Additionally, NICA held a meeting with a group of UHC representatives and offered some possible solutions as an alternative to their new policy.
Thank you to everyone who has followed along and shared in our efforts as well as those who have spearheaded efforts of their own. Your contributions helped to successfully push back against this harmful policy.
Introducing NICA’s New COVID-19 Antibody Treatment Resource Center!
In anticipation of several COVID-19 antibody treatments receiving Emergency Use Authorization from the FDA, NICA has been working closely with pharmaceutical manufacturers and governmental partners at Operation Warp Speed to ensure healthcare providers have the resources they need to safely and appropriately prescribe and administer these products.
NICA Surveys Help Inform the Integration of COVID-19 Therapeutics for Outpatient Administration
Most of you will know that in the last few weeks, many COVID-19 Antibody Treatments have received Emergency Use Authorization (EUA) from the FDA. Clinical trial data for Eli Lilly’s bamlanivimab and Regeneron’s REGN-CoV2 holds promise for significantly reducing the number of COVID-19 patients requiring hospitalization, thereby reducing the burden on the healthcare system.
NICA sent out surveys to providers in our network aimed to inform our industry’s role in battling this public health crisis.
As always, we appreciate your support, and we hope you and your patients are remaining safe during this uncertain period.
Thank you for your time,